Endpoints News

Lilly wins approval of anti-obesity pill orforglipron, setting up new battle with Novo

Now Eli Lilly has an obesity pill, too.

This report was first published by Endpoints News. To see the original version, click here

Now Eli Lilly has an obesity pill, too.

On Wednesday, the FDA approved orforglipron, the agency announced. It will be sold as Foundayo, and Lilly said it plans to sell a starting dose for $149 a month and higher doses for as much as $349 a month.

您已阅读25%(335字),剩余75%(1023字)包含更多重要信息,订阅以继续探索完整内容,并享受更多专属服务。
版权声明:本文版权归Endpoints News所有,未经允许任何单位或个人不得转载,复制或以任何其他方式使用本文全部或部分,侵权必究。
设置字号×
最小
较小
默认
较大
最大
分享×